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ABSTRACT
Introduction: A relatively novel application for
dermoscopy is its use in the monitoring of
topical treatment response for non-melanoma
skin cancer. Basal cell carcinoma (BCC) is the
most frequent type of skin cancer in humans.
Surgical excision is still considered the
‘‘gold-standard’’ of treatment. However, a
number of topical therapies are now available
for the treatment of different types of basal cell
carcinoma.
Case Report: This case report exemplifies the
usefulness of dermoscopy in the monitoring of
residual disease after incomplete surgical
excision and also in the monitoring of topical
treatment response. Imiquimod 5% cream acts
as a topical immune response modifier
promoting a Th-1 immune response
enhancing the removal of neoplastic cells and
has proven to reduce deregulated Hedgehog
(HH)/GLI signal strength independent of
Toll-like receptor signaling, which makes it a
valuable adjuvant topical therapy for the
treatment of basal cell carcinoma.
Conclusion: Imiquimod 5% cream is a valuable
adjuvant therapy for the treatment of
incompletely excised BCC. This case report
adds further evidence to the usefulness of
dermoscopy in the assessment and monitoring
of treatment outcome.
Keywords: Adjuvant; Basal cell; Carcinoma;
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INTRODUCTION
Dermoscopy is a valuable noninvasive
technique that increases diagnostic accuracy in
melanoma and non-melanoma skin cancer [1,
2]. Recently, its use as an aid in the monitoring
of topical treatment response has also been
described [2–4]. Basal cell carcinoma (BCC) is
the most frequent type of skin cancer in
humans. Surgical excision is still considered
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the ‘‘gold-standard’’ of treatment. However, a
number of topical therapies are now available
for the treatment of different types of basal cell
carcinoma. Despite the fact that BCC is
associated with a low mortality and very rarely
gives rise to metastatic disease, delays in its
correct diagnosis and treatment prolong patient
morbidity and increase the cost of care.
Dermoscopy has also shown to be useful in
the assessment of early recurrence or tumor
persistence. Dermoscopic criteria such as
pigmented structures, ulceration and
arborizing vessels have been suggested to
predict the presence of residual disease
(residual disease-associated dermoscopic
criteria) [4, 5].
This case report exemplifies the usefulness of
dermoscopy in the assessment of residual
disease after incomplete surgical excision and
also in the monitoring of topical treatment
response.
CASE REPORT
An otherwise healthy, 92-year-old woman was
seen for the evaluation and treatment of a
‘‘long-standing’’ nodular lesion on the tip of
her nose. The lesion was characterized as a
solitary, 5 mm, smooth, nodular, pearly tumor
with telangiectasia (Fig. 1). Dermoscopy
confirmed the diagnosis of nodular BCC
because of the presence of telangiectasia and
arborizing vessels (Fig. 2). The patient was
completely asymptomatic. Surgical excision
with 5 mm safety margins was performed. The
wound healed by secondary intention with daily
topical application of a pirfenidone gel (Fig. 3)
(Kitoscell-Q, Cell Therapy and Technology, S.A.
de C.V., Mexico). Histopathologic examination
revealed a neoformation arising from the
epidermis proliferating into the papillary and
Fig. 1 The lesion on the nose was characterized as a
solitary, 5 mm, smooth, nodular, pearly tumor with
telangiectasia
Fig. 2 Dermoscopy conﬁrmed the diagnosis of nodular
basal cell carcinoma because of the presence of
telangiectasia and arborizing vessels
Fig. 3 Wound healed by secondary intention with daily
topical application of a pirfenidone gel
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reticular dermis. It was constituted by an
epithelial tumor with basaloid-appearing cells
disposed in palisade at the periphery of the
tumor nests. The neoplastic cells had large
hyperchromatic nuclei with mitosis and
individual cellular necrosis. The tumoral nests
were surrounded by a lymphocytic inflammatory
infiltrate and a fibromyxoid stroma with stromal
Fig. 4 a (910, 920) and b (940). Histology conﬁrmed the diagnosis of inﬁltrating nodular basal cell carcinoma and
remains of tumoral cells within the wound bed and deep margins
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retraction artifact in certain areas. The tumor
extended into the deep margins where tumoral
nests were smaller, with angular shapes and
interspersed by a more fibrous stroma. Histology
confirmed the diagnosis of infiltrating nodular
BCC and remains of tumoral cells within the
wound bed and deep margins (Fig. 4). Six weeks
after the incomplete surgical excision, the
esthetic result was acceptable (Fig. 5). However,
dermoscopy confirmed the persistence of the
tumor characterized by a large arborizing vessel
(Fig. 6). The patient and her family members
denied a second surgical intervention and/or
radiotherapy. For this reason and due to the ease
of at-home application, daily topical treatment
with 5% imiquimod cream for 8 weeks was
started (Fig. 7). Follow-up was performed every
3 weeks. Clinically and dermoscopically the
patient revealed an appropriate response to the
topical treatment characterized mainly by
erythema and mild ulceration (Fig. 8). Four
weeks after the end of treatment, the clinical
esthetic result was acceptable (Fig. 9). At
12 months after the end of treatment
dermoscopy confirmed the absence of any signs
of recurrence (Fig. 10). The patient was last seen
Fig. 6 Dermoscopy conﬁrmed the persistence of the
tumor characterized by a large arborizing vessel
Fig. 5 Six weeks after the incomplete surgical excision the
esthetic result was acceptable
Fig. 7 a, b Daily topical treatment with 5% imiquimod
cream was started
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23 months after the end of treatment without
any signs of recurrence and dermoscopy
confirmed the eradication residual disease
(Fig. 11). All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the study.
Fig. 8 a–f Clinically and dermoscopically the patient
revealed an appropriate response to the topical treatment
characterized mainly by erythema and mild ulceration
Fig. 8 continued
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DISCUSSION
Basal cell carcinoma is the most frequent cancer of
the skin and its incidence is increasing worldwide
[4]. Surgery, including Mohs micrographic
surgery, is considered the ‘‘gold standard’’ of
treatment and the most effective in terms of
recurrence rates. Rates of incomplete excision of
BCC range from 4% to 16.6% [6]. Incomplete
excision has been associated with various
recurrence rates ranging from 26% to 67% and
50% of recurrences occur within the next
6–12 months [6]. Certain anatomic locations
such as the nose and inner canthus, as well as
certain histologic subtypes such as infiltrative and
multifocal, have been associated as predictive
factors for incomplete excision [6]. In cases where
the surgical intervention is unable to completely
remove the tumor, adjuvant therapy such as a
second surgical procedure, radiotherapy,
photodynamic therapy and topical
immunotherapy are used [7]. Imiquimod is a
Toll-like receptor-7/8 (TLR-7/8) agonist that acts
as a topical immune response modifier and has
been reported as a non-surgical alternative for the
treatment of BCC, particularly for the superficial
subtype [7, 8]. Topical imiquimod 5% cream
promotes a Th-1 immune response aimed at
Fig. 9 Four weeks after the end of 5% imiquimod
treatment the clinical esthetic result was acceptable
Fig. 10 One year later the patient had no signs of
recurrence conﬁrmed by dermoscopy
Fig. 11 Clinical and dermoscopic appearance 23 months
after the end of treatment. Dermoscopy shows no signs of
tumor recurrence and conﬁrms eradication of residual
disease
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enhancing the removal of neoplastic cells.
Recently, imiquimod 5% cream has been
described as a novel alternative to reduce
deregulated Hedgehog (HH)/GLI signal,
independent of TLR signaling. Small molecule
targeting of HH signaling by inhibiting the
essential pathway effector smoothened has
proven exceptionally efficient for the treatment
of advanced and metastatic basal cell carcinoma.
However, severe side effects, limited response
rates, and rapid development of drug resistance
may limit the therapeutic success of SMO
antagonists. This reflects the need for the
identification of alternative and additional
strategies repressing oncogenic HH signaling [9].
Imiquimod 5% may be one of such alternatives as
a topical, safe and relatively easy to use drug for
the treatment of different BCC subtypes as
adjuvant or neoadjuvant therapy [10].
CONCLUSION
Our case report exemplifies that dermoscopy is a
valuable diagnostic aid that also serves to assess
tumor recurrence/residual disease and to monitor
topical treatment response. It also adds further
evidence to the use of imiquimod as an important
topical neoadjuvant or adjuvant therapy for the
treatment of BCC and residual disease in cases
with incomplete surgical excision [10, 11].
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